{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T03:13:35Z","timestamp":1792725215760,"version":"4.5.0"},"reference-count":114,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100001744","name":"Mayday Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001744","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Brain, Behavior, and Immunity"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.bbi.2024.10.031","type":"journal-article","created":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T19:48:33Z","timestamp":1730490513000},"page":"903-913","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["An initial investigation of transcutaneous delivery of plasmid DNA encoding interleukin-10 for the treatment of psoriatic skin conditions"],"prefix":"10.1016","volume":"123","author":[{"given":"Igor","family":"Rafael Correia Rocha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maggie R.","family":"Finch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayson B.","family":"Ball","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael E.","family":"Harland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madison","family":"Clements","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Green-Fulgham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guiyun","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Banov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5870-388X","authenticated-orcid":false,"given":"Linda R.","family":"Watkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bbi.2024.10.031_b0010","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2174\/1871530318666180821161629","article-title":"Variation at Interleukin-10 Locus Represents Susceptibility to Psoriasis in North Indian Population","volume":"19","author":"Aadil","year":"2019","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"issue":"17","key":"10.1016\/j.bbi.2024.10.031_b0015","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1093\/nar\/25.17.3389","article-title":"Gapped BLAST and PSI-BLAST: A New Generation of Protein Database Search Programs","volume":"25","author":"Altschul","year":"1997","journal-title":"Nucleic Acids Res."},{"issue":"8","key":"10.1016\/j.bbi.2024.10.031_b0020","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1001\/jamadermatol.2021.2007","article-title":"Psoriasis Prevalence in Adults in the United States","volume":"157","author":"Armstrong","year":"2021","journal-title":"JAMA Dermatol"},{"issue":"12","key":"10.1016\/j.bbi.2024.10.031_b0025","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1007\/s004030050467","article-title":"Interleukin-10 in Cutaneous Disorders: Implications for Its Pathophysiological Importance and Therapeutic Use","volume":"291","author":"Asadullah","year":"1999","journal-title":"Arch Dermatol Res"},{"issue":"1","key":"10.1016\/j.bbi.2024.10.031_b0030","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1517\/13543784.9.1.95","article-title":"The Treatment of Psoriasis with IL-10: Rationale and Review of the First Clinical Trials","volume":"9","author":"Asadullah","year":"2000","journal-title":"Expert Opin Investig Drugs"},{"issue":"2","key":"10.1016\/j.bbi.2024.10.031_b0035","doi-asserted-by":"crossref","first-page":"185","DOI":"10.2174\/1568010043343886","article-title":"Interleukin-10: An Important Immunoregulatory Cytokine With Major Impact on Psoriasis","volume":"3","author":"Asadullah","year":"2004","journal-title":"CDTIA"},{"issue":"2","key":"10.1016\/j.bbi.2024.10.031_b0040","doi-asserted-by":"crossref","first-page":"e13610","DOI":"10.1111\/srt.13610","article-title":"Evaluation of a Compounding Phospholipid Base for the Percutaneous Absorption of High Molecular Weight Drugs Using the Franz Finite Dose Model","volume":"30","author":"Banov","year":"2024","journal-title":"Skin Res. Technol."},{"issue":"2","key":"10.1016\/j.bbi.2024.10.031_b0045","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s11154-017-9411-6","article-title":"Vitamin D and Its Role in Psoriasis: An Overview of the Dermatologist and Nutritionist","volume":"18","author":"Barrea","year":"2017","journal-title":"Rev Endocr Metab Disord"},{"issue":"2","key":"10.1016\/j.bbi.2024.10.031_b0050","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/pme.12899","article-title":"Evaluation of the Percutaneous Absorption of Ketamine HCl, Gabapentin, Clonidine HCl, and Baclofen, in Compounded Transdermal Pain Formulations, Using the Franz Finite Dose Model","volume":"17","author":"Bassani","year":"2016","journal-title":"Pain Med"},{"issue":"2","key":"10.1016\/j.bbi.2024.10.031_b0055","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1080\/00325481.2016.1144448","article-title":"Characterization of the Percutaneous Absorption of Ketoprofen Using the Franz Skin Finite Dose Model","volume":"128","author":"Bassani","year":"2016","journal-title":"Postgrad. Med."},{"issue":"4","key":"10.1016\/j.bbi.2024.10.031_b0060","doi-asserted-by":"crossref","first-page":"740","DOI":"10.3390\/vaccines11040740","article-title":"Characteristics of Patients Experiencing a Flare of Generalized Pustular Psoriasis: A Multicenter Observational Study","volume":"11","author":"Bellinato","year":"2023","journal-title":"Vaccines"},{"issue":"1","key":"10.1016\/j.bbi.2024.10.031_b0065","doi-asserted-by":"crossref","DOI":"10.23736\/S2784-8671.20.06878-9","article-title":"Analysis of Key Markers: IL-10\/sHLA-G in Psoriasis Patients and the Identification of 14-Bp INDEL in the HLA-G Gene","volume":"157","author":"Bieniek-Kobuszewska","year":"2022","journal-title":"Ital J Dermatol Venereol"},{"key":"10.1016\/j.bbi.2024.10.031_b0070","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.clim.2017.06.002","article-title":"TCR + CD3 + CD4 \u2212 CD8 \u2212 Effector T Cells in Psoriasis","volume":"181","author":"Brandt","year":"2017","journal-title":"Clin. Immunol."},{"issue":"6","key":"10.1016\/j.bbi.2024.10.031_b0075","first-page":"504","article-title":"Skin Permeation and Antinociception of Topical Gabapentin Formulations","volume":"18","author":"Bryson","year":"2014","journal-title":"Int J Pharm Compd"},{"issue":"4","key":"10.1016\/j.bbi.2024.10.031_b0080","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/cmi.2012.15","article-title":"New Insights of T Cells in the Pathogenesis of Psoriasis","volume":"9","author":"Cai","year":"2012","journal-title":"Cell Mol Immunol"},{"issue":"2","key":"10.1016\/j.bbi.2024.10.031_b0085","first-page":"63","article-title":"Failure of Biologic Therapy in Psoriasis","volume":"40","author":"Cardona","year":"2021","journal-title":"P R Health Sci J"},{"issue":"4","key":"10.1016\/j.bbi.2024.10.031_b0090","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1007\/s12325-023-02468-3","article-title":"Apremilast Use in Severe Psoriasis: Real-World Data from Central and Eastern Europe","volume":"40","author":"Cetkovsk\u00e1","year":"2023","journal-title":"Adv Ther"},{"issue":"6","key":"10.1016\/j.bbi.2024.10.031_b0095","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3109\/10717541003762862","article-title":"Retinoic Acid and Dimethyl Sulfoxide Promote Efficient Delivery of Transgenes to Mouse Skin by Topically Transdermal Penetration","volume":"17","author":"Chen","year":"2010","journal-title":"Drug Deliv."},{"issue":"5","key":"10.1016\/j.bbi.2024.10.031_b0100","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1007\/s00403-024-02886-5","article-title":"Intermittent Fasting Alleviates IMQ-Induced Psoriasis-like Dermatitis via Reduced \u03b3\u03b4T17 and Monocytes in Mice","volume":"316","author":"Chen","year":"2024","journal-title":"Arch Dermatol Res"},{"issue":"1","key":"10.1016\/j.bbi.2024.10.031_b0105","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1006\/abio.1987.9999","article-title":"Single-Step Method of RNA Isolation by Acid Guanidinium Thiocyanate\u2013Phenol\u2013Chloroform Extraction","volume":"162","author":"Chomzynski","year":"1987","journal-title":"Anal. Biochem."},{"issue":"S1","key":"10.1016\/j.bbi.2024.10.031_b0110","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s40257-021-00654-z","article-title":"Clinical Course and Characteristics of Generalized Pustular Psoriasis","volume":"23","author":"Choon","year":"2022","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.bbi.2024.10.031_b0115","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.bbi.2023.04.002","article-title":"Intrathecal Non-Viral Interleukin-10 Gene Therapy Ameliorates Neuropathic Pain as Measured by Both Classical Static Allodynia and a Novel Supra-Spinally Mediated Pain Assay, the Two-Arm Rodent Somatosensory (TARS) Task","volume":"111","author":"Clements","year":"2023","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.bbi.2024.10.031_b0120","doi-asserted-by":"crossref","unstructured":"Dai, X.; Permana, A. D.; Li, M.; Habibie; Nur Amir, M.; Peng, K.; Zhang, C.; Dai, H.; Paredes, A. J.; Vora, L. K.; Donnelly, R. F. Calcipotriol Nanosuspension-Loaded Trilayer Dissolving Microneedle Patches for the Treatment of Psoriasis: In Vitro Delivery and In Vivo Antipsoriatic Activity Studies. Mol. Pharmaceutics 2024, 21 (6), 2813\u20132827. 10.1021\/acs.molpharmaceut.3c01223.","DOI":"10.1021\/acs.molpharmaceut.3c01223"},{"issue":"6","key":"10.1016\/j.bbi.2024.10.031_b0125","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1111\/bjd.12230","article-title":"Is the Prevalence of Psoriasis Increasing? A 30-Year Follow-up of a Population-Based Cohort: Is the Prevalence of Psoriasis Increasing?","volume":"168","author":"Danielsen","year":"2013","journal-title":"Br. J. Dermatol."},{"issue":"4","key":"10.1016\/j.bbi.2024.10.031_b0130","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/1346-8138.16732","article-title":"Dissolving Microneedles for Effective and Painless Intradermal Drug Delivery in Various Skin Conditions: A Systematic Review","volume":"50","author":"De Decker","year":"2023","journal-title":"J. Dermatol."},{"issue":"2","key":"10.1016\/j.bbi.2024.10.031_b0135","first-page":"22","article-title":"Topical Corticosteroid Therapy for Psoriasis-A Review of Clobetasol Propionate 0.025% Cream and the Clinical Relevance of Penetration Modification","volume":"13","author":"Del Rosso","year":"2020","journal-title":"J Clin Aesthet Dermatol"},{"issue":"1","key":"10.1016\/j.bbi.2024.10.031_b0140","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/1742-2094-11-92","article-title":"Improvement of Spinal Non-Viral IL-10gene Delivery by D-Mannose as a Transgene Adjuvant to Control Chronic Neuropathic Pain","volume":"11","author":"Dengler","year":"2014","journal-title":"J Neuroinflammation"},{"issue":"3","key":"10.1016\/j.bbi.2024.10.031_b0145","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1189\/jlb.0408249","article-title":"Comprehensive Biomarker Monitoring in Cytokine Therapy: Heterogeneous, Time-Dependent, and Persisting Immune Effects of Interleukin-10 Application in Psoriasis","volume":"85","author":"D\u00f6cke","year":"2009","journal-title":"J. Leukoc. Biol."},{"issue":"4","key":"10.1016\/j.bbi.2024.10.031_b0150","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/74480","article-title":"Efficient Delivery of Transgenes to Human Hair Follicle Progenitor Cells Using Topical Lipoplex","volume":"18","author":"Domashenko","year":"2000","journal-title":"Nat Biotechnol"},{"issue":"6","key":"10.1016\/j.bbi.2024.10.031_b0155","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1002\/ejp.817","article-title":"Topical Prazosin Attenuates Sensitivity to Tactile Stimuli in Patients with Complex Regional Pain Syndrome","volume":"20","author":"Drummond","year":"2016","journal-title":"Eur. J. Pain"},{"issue":"10","key":"10.1016\/j.bbi.2024.10.031_b0160","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1039\/D3TB02643D","article-title":"Microneedle-Assisted Percutaneous Delivery of Methotrexate-Loaded Nanoparticles Enabling Sustained Anti-Inflammatory Effects in Psoriasis Therapy","volume":"12","author":"Du","year":"2024","journal-title":"J. Mater. Chem. B"},{"key":"10.1016\/j.bbi.2024.10.031_b0165","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.812774","article-title":"Toll-Like Receptor Signaling and Its Role in Cell-Mediated Immunity","volume":"13","author":"Duan","year":"2022","journal-title":"Front. Immunol."},{"issue":"8","key":"10.1016\/j.bbi.2024.10.031_b0170","first-page":"42","article-title":"Methotrexate Mechanism of Action in Plaque Psoriasis: Something New in the Old View","volume":"15","author":"El-Esawy","year":"2022","journal-title":"J Clin Aesthet Dermatol"},{"issue":"3","key":"10.1016\/j.bbi.2024.10.031_b0175","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.jaad.2019.04.042","article-title":"Joint American Academy of Dermatology-National Psoriasis Foundation Guidelines of Care for the Management and Treatment of Psoriasis with Phototherapy","volume":"81","author":"Elmets","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"issue":"19","key":"10.1016\/j.bbi.2024.10.031_b0180","doi-asserted-by":"crossref","first-page":"7228","DOI":"10.3390\/ijms21197228","article-title":"Immunological Memory in Imiquimod-Induced Murine Model of Psoriasiform Dermatitis","volume":"21","author":"Fenix","year":"2020","journal-title":"IJMS"},{"issue":"2","key":"10.1016\/j.bbi.2024.10.031_b0185","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jneumeth.2005.06.026","article-title":"Rapid Isolation of Highly Enriched and Quiescent Microglia from Adult Rat Hippocampus: Immunophenotypic and Functional Characteristics","volume":"151","author":"Frank","year":"2006","journal-title":"J. Neurosci. Methods"},{"issue":"3","key":"10.1016\/j.bbi.2024.10.031_b0190","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/j.jid.2021.06.019","article-title":"Mouse Models of Psoriasis: A Comprehensive Review","volume":"142","author":"Gangwar","year":"2022","journal-title":"J, Invest. Dermatol."},{"issue":"7","key":"10.1016\/j.bbi.2024.10.031_b0195","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1111\/ced.12715","article-title":"Psoriatic Alopecia","volume":"40","author":"George","year":"2015","journal-title":"Clin Exp Dermatol"},{"issue":"1\u20132","key":"10.1016\/j.bbi.2024.10.031_b0200","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/S0008-8749(02)00517-8","article-title":"Plasmacytoid Dendritic Cells Produce Cytokines and Mature in Response to the TLR7 Agonists","volume":"218","author":"Gibson","year":"2002","journal-title":"Imiquimod and Resiquimod. Cellular Immunology"},{"issue":"3","key":"10.1016\/j.bbi.2024.10.031_b0205","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/exd.13758","article-title":"Serum Level of IL -4 Predicts Response to Topical Immunotherapy with Diphenylcyclopropenone in Alopecia Areata","volume":"29","author":"Gong","year":"2020","journal-title":"Exp. Dermatol."},{"key":"10.1016\/j.bbi.2024.10.031_b0210","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.bbi.2016.05.012","article-title":"Behavioral Assessment of Neuropathic Pain, Fatigue, and Anxiety in Experimental Autoimmune Encephalomyelitis (EAE) and Attenuation by Interleukin-10 Gene Therapy","volume":"59","author":"Grace","year":"2017","journal-title":"Brain Behav. Immun."},{"issue":"2","key":"10.1016\/j.bbi.2024.10.031_b0215","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jdermsci.2015.11.003","article-title":"IL-10-Producing Regulatory B Cells Are Decreased in Patients with Psoriasis","volume":"81","author":"Hayashi","year":"2016","journal-title":"J. Dermatol. Sci."},{"issue":"1","key":"10.1016\/j.bbi.2024.10.031_b0220","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/71866","article-title":"The Hair Follicle as a Gene Therapy Target","volume":"18","author":"Hoffman","year":"2000","journal-title":"Nat Biotechnol"},{"issue":"1","key":"10.1016\/j.bbi.2024.10.031_b0225","doi-asserted-by":"crossref","first-page":"3685","DOI":"10.1038\/s41598-019-39903-x","article-title":"Methodological Refinement of Aldara-Induced Psoriasiform Dermatitis Model in Mice","volume":"9","author":"Horv\u00e1th","year":"2019","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.bbi.2024.10.031_b0230","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s12026-023-09366-4","article-title":"Efficacy and Safety of IL-23 Inhibitors in the Treatment of Psoriatic Arthritis: A Meta-Analysis Based on Randomized Controlled Trials","volume":"71","author":"Huang","year":"2023","journal-title":"Immunol Res"},{"issue":"2","key":"10.1016\/j.bbi.2024.10.031_b0235","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0009-9236(97)90065-5","article-title":"Pharmacodynamics of Subcutaneous Recombinant Human Interleukin-10 in Healthy Volunteers*","volume":"62","author":"Huhn","year":"1997","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.bbi.2024.10.031_b0240","first-page":"119","article-title":"Interleukin 10 Promotor Gene Polymorphism in the Pathogenesis of Psoriasis","volume":"28","author":"Isac","year":"2019","journal-title":"Acta Dermatovenerol Alp Pannonica Adriat"},{"issue":"1","key":"10.1016\/j.bbi.2024.10.031_b0245","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1615\/CritRevImmunol.v32.i1.30","article-title":"Role of Interleukin 10 Transcriptional Regulation in Inflammation and Autoimmune Disease","volume":"32","author":"Iyer","year":"2012","journal-title":"Crit Rev Immunol"},{"issue":"9","key":"10.1016\/j.bbi.2024.10.031_b0250","doi-asserted-by":"crossref","first-page":"789","DOI":"10.3390\/pharmaceutics12090789","article-title":"Advanced Characterization of Imiquimod-Induced Psoriasis-Like Mouse Model","volume":"12","author":"Jabeen","year":"2020","journal-title":"Pharmaceutics"},{"issue":"7","key":"10.1016\/j.bbi.2024.10.031_b0255","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1038\/jid.2013.57","article-title":"A Toll-Like Receptor 7, 8, and 9 Antagonist Inhibits Th1 and Th17 Responses and Inflammasome Activation in a Model of IL-23-Induced Psoriasis","volume":"133","author":"Jiang","year":"2013","journal-title":"J, Invest. Dermatol."},{"issue":"2","key":"10.1016\/j.bbi.2024.10.031_b0260","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.cyto.2014.01.008","article-title":"Polymorphisms in the TNF-\u03b1 and IL-10 Gene Promoters and Risk of Psoriasis and Correlation with Disease Severity","volume":"66","author":"Karam","year":"2014","journal-title":"Cytokine"},{"issue":"2","key":"10.1016\/j.bbi.2024.10.031_b0265","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/exd.14688","article-title":"Oestrogen Inhibits Psoriasis-like Dermatitis Induced by Imiquimod in Mice in Relation to Increased IL -10 Producing Cells despite Elevated Expression of IL -22, IL -23, IL -17 mRNA","volume":"32","author":"Kobayashi","year":"2023","journal-title":"Exp. Dermatol."},{"issue":"11","key":"10.1016\/j.bbi.2024.10.031_b0270","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1038\/npp.2017.82","article-title":"Opioid Self-Administration Is Attenuated by Early-Life Experience and Gene Therapy for Anti-Inflammatory IL-10 in the Nucleus Accumbens of Male Rats","volume":"42","author":"Lacagnina","year":"2017","journal-title":"Neuropsychopharmacol"},{"issue":"5","key":"10.1016\/j.bbi.2024.10.031_b0275","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.bbi.2006.10.012","article-title":"Intrathecal Interleukin-10 Gene Therapy Attenuates Paclitaxel-Induced Mechanical Allodynia and Proinflammatory Cytokine Expression in Dorsal Root Ganglia in Rats","volume":"21","author":"Ledeboer","year":"2007","journal-title":"Brain Behav. Immun."},{"issue":"7","key":"10.1016\/j.bbi.2024.10.031_b0280","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/s00011-012-0458-2","article-title":"Associations between Interleukin-10 Polymorphisms and Susceptibility to Psoriasis: A Meta-Analysis","volume":"61","author":"Lee","year":"2012","journal-title":"Inflamm. Res."},{"issue":"17","key":"10.1016\/j.bbi.2024.10.031_b0285","doi-asserted-by":"crossref","first-page":"13313","DOI":"10.3390\/ijms241713313","article-title":"Challenges and Future Trends in the Treatment of Psoriasis","volume":"24","author":"Lee","year":"2023","journal-title":"IJMS"},{"issue":"6","key":"10.1016\/j.bbi.2024.10.031_b0290","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1517\/14740330903393732","article-title":"A Review of Acitretin for the Treatment of Psoriasis","volume":"8","author":"Lee","year":"2009","journal-title":"Expert Opin. Drug Saf."},{"issue":"6","key":"10.1016\/j.bbi.2024.10.031_b0295","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/jgm.1459","article-title":"Gene Therapy for Psoriasis in the K14-VEGF Transgenic Mouse Model by Topical Transdermal Delivery of Interleukin-4 Using Ultradeformable Cationic Liposome","volume":"12","author":"Li","year":"2010","journal-title":"J. Gene Med."},{"key":"10.1016\/j.bbi.2024.10.031_b0300","article-title":"N-Acylethanolamine Acid Amidase (NAAA) Exacerbates Psoriasis Inflammation by Enhancing Dendritic Cell (DCs) Maturation","volume":"185","author":"Li","year":"2022","journal-title":"Pharmacol. Res."},{"issue":"1","key":"10.1016\/j.bbi.2024.10.031_b0305","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12865-021-00401-3","article-title":"Application of Imiquimod-Induced Murine Psoriasis Model in Evaluating Interleukin-17A Antagonist","volume":"22","author":"Li","year":"2021","journal-title":"BMC Immunol"},{"key":"10.1016\/j.bbi.2024.10.031_b0310","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2147\/PTT.S101232","article-title":"Erythrodermic Psoriasis: Pathophysiology and Current Treatment Perspectives","volume":"6","author":"Liao","year":"2016","journal-title":"PTT"},{"key":"10.1016\/j.bbi.2024.10.031_b0315","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.2147\/DDDT.S447780","article-title":"RNA-Based Antipsoriatic Gene Therapy: An Updated Review Focusing on Evidence from Animal Models","volume":"18","author":"Lin","year":"2024","journal-title":"DDDT"},{"issue":"4","key":"10.1016\/j.bbi.2024.10.031_b0320","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2\u2212\u0394\u0394CT Method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"issue":"7","key":"10.1016\/j.bbi.2024.10.031_b0325","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.3390\/ijms20071670","article-title":"Infiltration of T Cells into a Three-Dimensional Psoriatic Skin Model Mimics Pathological Key Features","volume":"20","author":"Lorthois","year":"2019","journal-title":"IJMS"},{"issue":"1","key":"10.1016\/j.bbi.2024.10.031_b0330","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1080\/09546634.2020.1757017","article-title":"Effectiveness of Cyclosporine A in Patients with Moderate to Severe Plaque Psoriasis in a Real-Life Clinical Setting in Italy: The TRANSITION Study","volume":"33","author":"Marsili","year":"2022","journal-title":"J. Dermatol. Treat."},{"issue":"12","key":"10.1016\/j.bbi.2024.10.031_b0335","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1093\/rheumatology\/kez204","article-title":"Apremilast Increases IL-10-Producing Regulatory B Cells and Decreases Proinflammatory T Cells and Innate Cells in Psoriatic Arthritis and Psoriasis","volume":"58","author":"Mavropoulos","year":"2019","journal-title":"Rheumatology"},{"key":"10.1016\/j.bbi.2024.10.031_b0340","doi-asserted-by":"crossref","DOI":"10.1186\/1744-8069-1-9","article-title":"Controlling Neuropathic Pain by Adeno-Associated Virus Driven Production of the Anti-Inflammatory Cytokine, Interleukin-10","volume":"1","author":"Milligan","year":"2005","journal-title":"Mol Pain"},{"issue":"1","key":"10.1016\/j.bbi.2024.10.031_b0345","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.pain.2006.07.009","article-title":"Repeated Intrathecal Injections of Plasmid DNA Encoding Interleukin-10 Produce Prolonged Reversal of Neuropathic Pain","volume":"126","author":"Milligan","year":"2006","journal-title":"Pain"},{"issue":"1","key":"10.1016\/j.bbi.2024.10.031_b0350","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1080\/10408398.2017.1358139","article-title":"Immune Modulation by Curcumin: The Role of Interleukin-10","volume":"59","author":"Mollazadeh","year":"2019","journal-title":"Crit. Rev. Food Sci. Nutr."},{"issue":"1","key":"10.1016\/j.bbi.2024.10.031_b0355","doi-asserted-by":"crossref","first-page":"16570","DOI":"10.1038\/s41598-017-16707-5","article-title":"The Systemic Response to Topical Aldara Treatment Is Mediated Through Direct TLR7 Stimulation as Imiquimod Enters the Circulation","volume":"7","author":"Nerurkar","year":"2017","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.bbi.2024.10.031_b0360","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/ar.23690","article-title":"Effect of Topical Application of Black Seed Oil on Imiquimod-Induced Psoriasis-like Lesions in the Thin Skin of Adult Male Albino Rats","volume":"301","author":"Okasha","year":"2018","journal-title":"Anat. Rec."},{"issue":"2","key":"10.1016\/j.bbi.2024.10.031_b0365","doi-asserted-by":"crossref","first-page":"125","DOI":"10.4103\/ijp.IJP_506_19","article-title":"Development of a Psoriatic-like Skin Inflammation Rat Model Using Imiquimod as an Inducing Agent","volume":"53","author":"Parmar","year":"2021","journal-title":"Indian J Pharmacol"},{"issue":"1","key":"10.1016\/j.bbi.2024.10.031_b0370","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/s41392-023-01648-5","article-title":"Control of CD4+ T Cells to Restrain Inflammatory Diseases via Eukaryotic Elongation Factor 2 Kinase","volume":"8","author":"Peng","year":"2023","journal-title":"Sig Transduct Target Ther"},{"key":"10.1016\/j.bbi.2024.10.031_b0375","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.3389\/fimmu.2018.03113","article-title":"T Cell Response to Infliximab in Exposed Patients: A Longitudinal Analysis","volume":"9","author":"Pratesi S.; Nencini F.; Grosso F.; Dies L.; Bormioli S.; Cammelli D.; Maggi E.; Matucci A.; Vultaggio A.; ABIRISK Consortium","year":"2019","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.bbi.2024.10.031_b0380","doi-asserted-by":"crossref","first-page":"e00512","DOI":"10.1002\/mgg3.512","article-title":"Lack of Association of the IL-1RN and IL-10 Polymorphisms with Risk of Psoriasis: A Meta-Analysis","volume":"7","author":"Qiao","year":"2019","journal-title":"Mol Genet Genomic Med"},{"issue":"6","key":"10.1016\/j.bbi.2024.10.031_b0385","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.clindermatol.2013.06.003","article-title":"Disorders of Hair Growth and the Pilosebaceous Unit: Facts and Controversies","volume":"31","author":"Ramos-e-Silva","year":"2013","journal-title":"Clin. Dermatol."},{"issue":"12","key":"10.1016\/j.bbi.2024.10.031_b0390","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/j.drudis.2020.09.023","article-title":"Psoriasis: Pathological Mechanisms, Current Pharmacological Therapies, and Emerging Drug Delivery Systems","volume":"25","author":"Rapalli","year":"2020","journal-title":"Drug Discov. Today"},{"issue":"2","key":"10.1016\/j.bbi.2024.10.031_b0395","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1046\/j.1523-1747.2001.01248.x","article-title":"Response of Psoriasis to Interleukin-10 Is Associated with Suppression of Cutaneous Type 1 Inflammation, Downregulation of the Epidermal Interleukin-8\/CXCR2 Pathway and Normalization of Keratinocyte Maturation","volume":"116","author":"Reich","year":"2001","journal-title":"J, Invest. Dermatol."},{"key":"10.1016\/j.bbi.2024.10.031_b0400","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jconrel.2024.02.009","article-title":"Substrate-Free Dissolving Microneedles with Barbed Shape to Increase Adhesion and Drug-Delivery Efficiency to Skin","volume":"368","author":"Ren","year":"2024","journal-title":"J. Control. Release"},{"issue":"23","key":"10.1016\/j.bbi.2024.10.031_b0405","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.2174\/1381612824666180807120017","article-title":"Current Non-Viral siRNA Delivery Systems as a Promising Treatment of Skin Diseases","volume":"24","author":"Rosa","year":"2018","journal-title":"CPD"},{"issue":"2","key":"10.1016\/j.bbi.2024.10.031_b0410","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1159\/000247418","article-title":"Psoriatic Alopecia: Acute and Chronic Hair Loss in 47 Patients with Scalp Psoriasis","volume":"185","author":"Runne","year":"1992","journal-title":"Dermatology"},{"key":"10.1016\/j.bbi.2024.10.031_b0415","article-title":"Lack of Systemic Effects from Intra-Articular XT-150 for the Treatment of Moderate to Severe Pain Due to OA of the Knee: Safety Results from a Phase 2","author":"Rutman","year":"2023","journal-title":"Trial"},{"key":"10.1016\/j.bbi.2024.10.031_b0005","doi-asserted-by":"crossref","unstructured":"Rutman, H. Efficacy of XT-150, a Novel Non-Viral Gene Therapy Delivering IL-10v, on Moderate to Severe Pain Due to Osteoarthritis of the Knee: Patient Subgroup Analysis; San Diego.; 2024.","DOI":"10.1016\/j.joca.2024.02.061"},{"issue":"10","key":"10.1016\/j.bbi.2024.10.031_b0420","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1111\/j.1600-0625.2007.00629.x","article-title":"Immunopathogenesis of Psoriasis","volume":"16","author":"Sabat","year":"2007","journal-title":"Exp. Dermatol."},{"issue":"3","key":"10.1016\/j.bbi.2024.10.031_b0425","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1002\/eji.1830270308","article-title":"Cytokine Stimulation of T Lymphocytes Regulates Their Capacity to Induce Monocyte Production of Tumor Necrosis Factor-\u03b1, but Not Interleukin-10: Possible Relevance to Pathophysiology of Rheumatoid Arthritis","volume":"27","author":"Sebbag","year":"1997","journal-title":"Eur J Immunol"},{"issue":"2","key":"10.1016\/j.bbi.2024.10.031_b0430","doi-asserted-by":"crossref","first-page":"133","DOI":"10.4212\/cjhp.v73i2.2979","article-title":"Compounded Topical Amitriptyline for Neuropathic Pain. In Vitro Release from Compounding Bases and Potential Correlation with Clinical Efficacy","volume":"73","author":"Shakshuki","year":"2020","journal-title":"Can J Hosp Pharm"},{"key":"10.1016\/j.bbi.2024.10.031_b0435","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2024.106711","article-title":"Methotrexate-Loaded Hyaluronan-Modified Liposomes Integrated into Dissolving Microneedles for the Treatment of Psoriasis","volume":"195","author":"Shen","year":"2024","journal-title":"Eur. J. Pharm. Sci."},{"issue":"10","key":"10.1016\/j.bbi.2024.10.031_b0440","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1038\/gt.2009.79","article-title":"Immunological Priming Potentiates Non-Viral Anti-Inflammatory Gene Therapy Treatment of Neuropathic Pain","volume":"16","author":"Sloane","year":"2009","journal-title":"Gene Ther"},{"issue":"1","key":"10.1016\/j.bbi.2024.10.031_b0445","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.bbi.2008.09.004","article-title":"Anti-Inflammatory Cytokine Gene Therapy Decreases Sensory and Motor Dysfunction in Experimental Multiple Sclerosis: MOG-EAE Behavioral and Anatomical Symptom Treatment with Cytokine Gene Therapy","volume":"23","author":"Sloane","year":"2009","journal-title":"Brain Behav. Immun."},{"issue":"4","key":"10.1016\/j.bbi.2024.10.031_b0450","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/gt.2009.21","article-title":"Long-Term Control of Neuropathic Pain in a Non-Viral Gene Therapy Paradigm","volume":"16","author":"Sloane","year":"2009","journal-title":"Gene Ther"},{"issue":"5","key":"10.1016\/j.bbi.2024.10.031_b0455","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s11095-010-0077-y","article-title":"Release of Plasmid DNA-Encoding IL-10 from PLGA Microparticles Facilitates Long-Term Reversal of Neuropathic Pain Following a Single Intrathecal Administration","volume":"27","author":"Soderquist","year":"2010","journal-title":"Pharm Res"},{"issue":"6","key":"10.1016\/j.bbi.2024.10.031_b0460","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1080\/10428190500054426","article-title":"Regression of Lymphomatous Skin Deposits in a Chronic Lymphocytic Leukemia Patient Treated with the Toll-like Receptor-7\/8 Agonist","volume":"46","author":"Spaner","year":"2005","journal-title":"Imiquimod. Leukemia & Lymphoma"},{"issue":"3","key":"10.1016\/j.bbi.2024.10.031_b0465","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/exd.14462","article-title":"The Hair Follicle-psoriasis Axis: Shared Regulatory Mechanisms and Therapeutic Targets","volume":"31","author":"Suzuki","year":"2022","journal-title":"Exp. Dermatol."},{"key":"10.1016\/j.bbi.2024.10.031_b0470","doi-asserted-by":"crossref","first-page":"S121","DOI":"10.1016\/j.joca.2023.01.074","article-title":"Functional Improvements In Knee Kinematics During Walking Gait Over Six Months Following Treatment With Xt-150: Pooled Results From Two Clinical Trials","volume":"31","author":"Thewlis","year":"2023","journal-title":"Osteoarthr. Cartil."},{"issue":"11","key":"10.1016\/j.bbi.2024.10.031_b0475","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1111\/ijd.14047","article-title":"Psoriasis: Implication to Disease and Therapeutic Strategies, with an Emphasis on Drug Delivery Approaches","volume":"57","author":"Todke","year":"2018","journal-title":"Int J Dermatology"},{"issue":"5","key":"10.1016\/j.bbi.2024.10.031_b0480","doi-asserted-by":"crossref","first-page":"6387","DOI":"10.15419\/bmrat.v11i5.885","article-title":"Effects of Imiquimod Application Durations on Psoriasis-like Lesions and Cytokine Expression in Mice","volume":"11","author":"Tran","year":"2024","journal-title":"Biomed. Res. Ther."},{"key":"10.1016\/j.bbi.2024.10.031_b0485","doi-asserted-by":"crossref","unstructured":"Trifunovi\u0107, J.; Miller, L.; Debeljak, \u017d.; Horvat, V. Pathologic Patterns of Interleukin 10 Expression \u2013 A Review. Biochem Med 2015, 25 (1), 36\u201348. 10.11613\/BM.2015.004.","DOI":"10.11613\/BM.2015.004"},{"issue":"5","key":"10.1016\/j.bbi.2024.10.031_b0490","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/1523-1747.ep12371679","article-title":"The Cytokine Network in Lesional and Lesion-Free Psoriatic Skin Is Characterized by a T-Helper Type 1 Cell-Mediated Response","volume":"101","author":"Uyemura","year":"1993","journal-title":"J, Invest. Dermatol."},{"issue":"9","key":"10.1016\/j.bbi.2024.10.031_b0495","doi-asserted-by":"crossref","first-page":"5836","DOI":"10.4049\/jimmunol.0802999","article-title":"Imiquimod-Induced Psoriasis-Like Skin Inflammation in Mice Is Mediated via the IL-23\/IL-17 Axis1","volume":"182","author":"van der Fits","year":"2009","journal-title":"J. Immunol."},{"issue":"9","key":"10.1016\/j.bbi.2024.10.031_b0500","doi-asserted-by":"crossref","first-page":"5836","DOI":"10.4049\/jimmunol.0802999","article-title":"Imiquimod-Induced Psoriasis-Like Skin Inflammation in Mice Is Mediated via the IL-23\/IL-17 Axis","volume":"182","author":"Van Der Fits","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.bbi.2024.10.031_b0505","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.bbi.2017.11.004","article-title":"Effects of Spinal Non-Viral Interleukin-10 Gene Therapy Formulated with d -Mannose in Neuropathic Interleukin-10 Deficient Mice: Behavioral Characterization, mRNA and Protein Analysis in Pain Relevant Tissues","volume":"69","author":"Vanderwall","year":"2018","journal-title":"Brain Behav. Immun."},{"issue":"8","key":"10.1016\/j.bbi.2024.10.031_b0510","doi-asserted-by":"crossref","first-page":"2300720","DOI":"10.1002\/mnfr.202300720","article-title":"Bcat2-Mediated Branched-Chain Amino Acid Catabolism Is Linked to the Aggravated Inflammation in Obese with Psoriasis Mice","volume":"68","author":"Wang","year":"2024","journal-title":"Molecular Nutrition Food Res"},{"key":"10.1016\/j.bbi.2024.10.031_b0515","doi-asserted-by":"crossref","first-page":"247","DOI":"10.5114\/ada.2016.61599","article-title":"Interleukin-17 Inhibitors. A New Era in Treatment of Psoriasis and Other Skin Diseases","volume":"4","author":"Wasilewska","year":"2016","journal-title":"Pdia"},{"key":"10.1016\/j.bbi.2024.10.031_b0520","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.bbi.2020.08.005","article-title":"Targeted Interleukin-10 Plasmid DNA Therapy in the Treatment of Osteoarthritis: Toxicology and Pain Efficacy Assessments","volume":"90","author":"Watkins","year":"2020","journal-title":"Brain Behav. Immun."},{"issue":"4","key":"10.1016\/j.bbi.2024.10.031_b0525","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1111\/j.1365-2133.1972.tb07424.x","article-title":"ABNORMAL HAIR SHAFTS IN PSORIASIS ON SCANNING ELECTRON MICROSCOPY*","volume":"87","author":"Wyatt","year":"1972","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.bbi.2024.10.031_b0530","doi-asserted-by":"crossref","DOI":"10.1177\/17448069241252384","article-title":"The Regulation of the PD-1\/PD-L1 Pathway in Imiquimod-Induced Chronic Psoriasis Itch and Itch Sensitization in Mouse","volume":"20","author":"Xu","year":"2024","journal-title":"Mol Pain"},{"issue":"8","key":"10.1016\/j.bbi.2024.10.031_b0535","doi-asserted-by":"crossref","first-page":"4409","DOI":"10.3390\/ijms25084409","article-title":"Pathogenesis of Alopecia Areata and Vitiligo: Commonalities and Differences","volume":"25","author":"Yamaguchi","year":"2024","journal-title":"IJMS"},{"key":"10.1016\/j.bbi.2024.10.031_b0540","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116705","article-title":"The Discovery of a Novel Pyrrolo[2,3-b]Pyridine as a Selective CDK8 Inhibitor Offers a New Approach against Psoriasis","volume":"175","author":"Yan","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bbi.2024.10.031_b0545","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3410\/M1-30","article-title":"The Role of TNF Inhibitors in Psoriasis Therapy: New Implications for Associated Comorbidities","volume":"1","author":"Yost","year":"2009","journal-title":"F1000 Med Rep"},{"issue":"10","key":"10.1016\/j.bbi.2024.10.031_b0550","doi-asserted-by":"crossref","first-page":"3809","DOI":"10.4049\/jimmunol.1602142","article-title":"Cutting Edge: Selective Oral ROCK2 Inhibitor Reduces Clinical Scores in Patients with Psoriasis Vulgaris and Normalizes Skin Pathology via Concurrent Regulation of IL-17 and IL-10","volume":"198","author":"Zanin-Zhorov","year":"2017","journal-title":"J. Immunol."},{"key":"10.1016\/j.bbi.2024.10.031_b0555","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.122109","article-title":"Glycyrrhizin Micellar Nanocarriers for Topical Delivery of Baicalin to the Hair Follicles: A Targeted Approach Tailored for Alopecia Treatment","volume":"625","author":"Zeng","year":"2022","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.bbi.2024.10.031_b0560","doi-asserted-by":"crossref","first-page":"1081256","DOI":"10.3389\/fimmu.2023.1081256","article-title":"The Roles of T Cells in Psoriasis","volume":"14","author":"Zhang","year":"2023","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.bbi.2024.10.031_b0565","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/s41419-022-04523-3","article-title":"Advances in the Pathogenesis of Psoriasis: From Keratinocyte Perspective","volume":"13","author":"Zhou","year":"2022","journal-title":"Cell Death Dis"},{"issue":"3","key":"10.1016\/j.bbi.2024.10.031_b0570","doi-asserted-by":"crossref","first-page":"460","DOI":"10.5114\/ada.2021.108445","article-title":"Treatments in Psoriasis: From Standard Pharmacotherapyto Nanotechnology Therapy","volume":"39","author":"Zhu","year":"2022","journal-title":"Pdia"}],"container-title":["Brain, Behavior, and Immunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S088915912400672X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S088915912400672X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T03:43:43Z","timestamp":1762314223000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S088915912400672X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":114,"alternative-id":["S088915912400672X"],"URL":"https:\/\/doi.org\/10.1016\/j.bbi.2024.10.031","relation":{},"ISSN":["0889-1591"],"issn-type":[{"value":"0889-1591","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An initial investigation of transcutaneous delivery of plasmid DNA encoding interleukin-10 for the treatment of psoriatic skin conditions","name":"articletitle","label":"Article Title"},{"value":"Brain, Behavior, and Immunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbi.2024.10.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}